A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients
Latest Information Update: 23 Oct 2024
At a glance
- Drugs 707 3SBio (Primary)
- Indications Endometrial cancer; Gynaecological cancer; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 21 Oct 2024 Status changed from not yet recruiting to recruiting.
- 01 Aug 2024 New trial record